Wednesday, August 4, 2010

Global sales of Velcade to reach $3 billion by 2015

The global sales of Velcade (a proteasome inhibitor) was about $1.4 billion in 2009 and is expected to reach $3 billion in 2015, a compound annual growth rate (CAGR) of 13.5% through 2015.

Learn about the current state of drug discovery in the ubiquitin proteasome research field, existing products on the market, and detailed analysis of the competitive environments, including new potential markets for current research projects. This report includes information about significant players in this field of study, trends, and challenges, and other information affecting drug discovery in the ubiquitin proteasome system (UPS)...

Use this report to:
  • Understand this emerging area of drug discovery and development
  • Learn about the major research trends in UPS that are going to affect further drug development in this area, identification of new drug candidates, and new technologies in assay development
  • Develop strategies and tools to evaluate potential commercial opportunities in this new field
  • Gain insight into competitors’ positions and which companies are closest to introducing new products to the market in the next couple of years.
To provide further information about this report we offer a Complimentary Introduction, available from our Website.

No comments:

Post a Comment

Bookmark and Share